SurvivorNet // Connect

The new gold standard for HCP-focused media.

Latest News

Stay up to date on the latest news brought to you in collaboration with leading experts

View all Articles

Weighing the Risks of Multiple Myeloma Therapy in the Time of COVID-19

As the COVID-19 pandemic spread across the country, cancer specialists had to weigh the risks of treating multiple myeloma to prevent morbidity and mortality, with the dangers of virus exposure in their patients. SurvivorNet's experts say treatment decisions often hinge on geographic location.

Learn More

Next Level HRD Testing and How to Make Better Decisions

Dr. Thomas Herzog notes the importance of an HRD test, “Getting an HRD for me would be important. I think the next gen sequencing doesn’t lead to new treatments all that often. My counter-argument to that is that we’re learning more and more. We really want to move the field forward and we need to get that information."

Learn More

Could Ibrutinib Combined With Other Targeted Therapies and Chemo Be ‘the Future’ of B-Cell Lymphoma Treatment?

New research is enhancing our understanding of ibrutinib -- a Bruton's tyrosine kinase (BTK) inhibitor used to treat several different types of lymphoma, including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma. It has also produced positive responses in B-cell lymphoma, but is so far only used in patients with relapsed/refractory disease.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

Past Events

Sep. 24, 2020 3:00pm EST

Key Developments in Multiple Myeloma and Adjusting to COVID-19

This session qualifies for CME credit.

Sep. 22, 2020 4:00pm EST

Key Developments in Ovarian Cancer and Adjusting to COVID-19

This session qualifies for CME credit.

Jul. 14, 2020 2:00pm EST

Key Developments in Multiple Myeloma in The Age of COVID-19 and Beyond

Thousands of physicians are struggling with new treatment protocols in the age Covid-19. On June 4th SurvivorNet held a collaborative conversation where opinion leaders addressed key topics.

May. 15, 2020 4:00pm EST

Key Developments in Ovarian Cancer in The Age of COVID-19 and Beyond

Thousands of physicians are struggling with new treatment protocols in the age Covid-19. On May 15th SurvivorNet held a collaborative conversation where opinion leaders addressed key topics.

Our Mission

Progress through collective wisdom and collaborative energy

Oncologists around the country told us they needed a better way to stay up to date and find support, so we created SurvivorNet Connect. It's a digital platform dedicated to advancing the science and practice of oncology by providing health care providers with a fresh perspective on professional education.

Events & Conferences

Collaborative Workshops

Thought Leadership

“Bringing health care professionals together in a collaborative independent environment is one of the most important things we can do to make an outsize impact”

- Steve Alperin - Founder/CEO SurvivorNet